James Campbell, PhD, MBA – Chief Executive Officer
Dr. Campbell has more than 20 years of international biotechnology research, management and leadership experience and has been involved in the creation and/or transformation of several Australian and international biotechnology companies. Dr. Campbell was previously the CFO and COO of ChemGenex Pharmaceuticals Limited (ASX:CXS) where, as a member of the executive team he helped transform a research-based company with a market capitalization of $10M to a company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA. In 2011 ChemGenex was sold to Teva for $230M. Since 2011 Dr. Campbell has assisted private biotechnology companies in Australia, New Zealand and the USA with capital raising and partnering negotiations. Dr. Campbell is a Non-Executive Director of Prescient Therapeutics Limited (ASX:PRX) and Invion Limited (ASX:IVX). Dr Campbell also sits on a number of academic and government biotechnology advisory panels.
Melanie Leydin, B.Bus (Acc. Corp. Law) – Company Secretary
Melanie Leydin holds a Bachelor of Business majoring in Accounting and Corporate Law. She is a member of the Institute of Chartered Accountants and is a Registered Company Auditor. She graduated from Swinburne University in 1997, became a Chartered Accountant in 1999 and since February 2000 has been the principal of chartered accounting firm, Leydin Freyer. The practice provides outsourced company secretarial and accounting services to public and private companies specialising in the Resources, technology, bioscience and biotechnology sector. Melanie has over 23 years’ experience in the accounting profession and has extensive experience in relation to public company responsibilities, including ASX and ASIC compliance, control and implementation of corporate governance, statutory financial reporting, reorganisation of Companies and shareholder relations.
Deanne Greenwood, PhD, MBA – Vice President, Business Development & Intellectual Property
Dr. Greenwood is responsible for commercialisation of Patrys’ antibody technology, relationship management and Patrys’ intellectual property portfolio. Dr. Greenwood has held various roles at Patrys since she joined in 2008. Prior to joining Patrys, Dr. Greenwood spent 10-years in academia conducting immunology research in the areas of vaccine development and autoimmunity, with the last four years at the Centre for Animal Biotechnology, The University of Melbourne. Dr. Greenwood has a PhD degree in Immunology from the Monash University and a Masters of Business Administration (Technology) from La Trobe University. Dr. Greenwood is a co-author on 11 publications on immunological related topics.
Valentina Dubljevic, MBB, BSc – Vice President, Scientific & Clinical Development
Ms. Dubljevic has over 17 years’ experience working as integral member of R&D teams on various projects in the areas of anti- cancer therapies, vaccine development, and diagnostics in both scientific and managerial roles. Having a strong interest in the commercial development of science she worked at the Monash University conducting research on malaria vaccine development; at Cytopia developing small molecule anti-cancer drugs and most recently at Monash Institute of Medical Research (MIMR) developing antibody therapies for cancer. Ms. Dubljevic joined Patrys in June 2012 and is responsible for Patrys’ scientific research and collaborations, project management, grants and management and co-ordination of pre-clinical, regulatory and clinical operations. Ms. Dubljevic holds a Bachelor of Biomedical Science degree from the Griffith University, Brisbane and a Masters in Biotechnology and Business degree from RMIT.